Sanochemia acquires majority shareholding in AlcaSynn
In cooperation with leading pharmaceutical players, AlcaSynn develops drugs on the basis of synthetic morphinan derivatives with a marked pharmacological profile for the treatment of pain, inflammation, Parkinson's and Alzheimer's. The company is headed by Dr. Peter Kayatz (CEO) and Dr. Mariana Spetea (CSO) and currently holds a patent portfolio consisting of 13 awarded patents and a further 26 patents pending.
The leading product candidate, AS006, is a strong, peripherally-acting painkiller (100 times stronger than morphine) which does not exhibit the adverse side effects characteristic of other opiates including respiratory depression, drowsiness and potential addiction. AS006 is currently in pre-clinical testing with clinical trials scheduled to begin in 2008.
Sanochemia's shareholding in AlcaSynn Pharmaceuticals GmbH represents a major strategic addition to its potential as a provider of specialty pharmaceuticals in its existing development segments. Key for Sanochemia is the synergy potential offered by utilising its synthesis plant located in Neufeld, Austria.
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.